Cost Effectiveness of Implementing a Universal Birth Hepatitis B Vaccination Program in Ontario

Overview

Journal Pharmacoeconomics

Specialty Pharmacology

Date 2023 Jan 28

PMID 36708500

Authors

John J Kim

Wasem Alsabbagh

William W L Wong

Affiliations

Soon will be listed here.

Abstract

Background And Objective: The World Health Organization recommends a universal hepatitis B vaccination within the first 24 h of birth. However, hepatitis B vaccines are given during adolescence in many jurisdictions including in Ontario, Canada. The objective of this study was to assess the cost effectiveness of shifting the hepatitis B vaccination timing from adolescence to birth.

Methods: A state-transition model of 18 health states representing the natural history of acute and chronic hepatitis B was developed to conduct a cost-utility analysis. Most input parameters were obtained from the Canadian literature or publicly available provincial data. The model followed a lifetime model time horizon with health outcomes and costs being discounted at 1.5% annually. Deterministic and probabilistic sensitivity analyses were performed to test the robustness of the model. Analyses were conducted from a public-payer perspective with all costs adjusted to 2021 Canadian dollars.

Results: Hepatitis B vaccination in newborns dominated the current strategy of adolescent vaccination. The probabilistic analysis showed that the newborn strategy was cost effective in 100% of the iterations at a willingness-to-pay threshold of $50,000/quality-adjusted life-year and cost saving in 79.39% of the iterations. A microsimulation projected that a newborn vaccination may lead to reductions in cases by 16.1% in acute hepatitis B, 43.2% in chronic hepatitis B, 48.2% in hepatocellular carcinoma, and 51.9% in hepatitis B liver-related death.

Conclusions: Our analysis suggests that changing the age of the hepatitis B vaccination recommendation from adolescent to newborn is cost effective and mostly a cost-saving strategy. Newborn vaccination may lead to cost and health benefits while aligning with best available evidence and guidance from the World Health Organization.

References

Lu C, Chiang B, Chi W, Chang M, Ni Y, Hsu H . Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology. 2004; 40(6):1415-20. DOI: 10.1002/hep.20490. View

Bruce M, Bruden D, Hurlburt D, Zanis C, Thompson G, Rea L . Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose. J Infect Dis. 2016; 214(1):16-22. DOI: 10.1093/infdis/jiv748. View

Krahn M, Guasparini R, Sherman M, Detsky A . Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program. Am J Public Health. 1998; 88(11):1638-44. PMC: 1508554. DOI: 10.2105/ajph.88.11.1638. View

Lee D, Park S . Cost-Effectiveness Analysis of Hepatitis B Vaccination Strategies to Prevent Perinatal Transmission in North Korea: Selective Vaccination vs. Universal Vaccination. PLoS One. 2016; 11(11):e0165879. PMC: 5089722. DOI: 10.1371/journal.pone.0165879. View

Tilson L, Thornton L, OFlanagan D, Johnson H, Barry M . Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation. Eur J Public Health. 2007; 18(3):275-82. DOI: 10.1093/eurpub/ckm123. View

Wong W, Woo G, Heathcote E, Krahn M . Cost effectiveness of screening immigrants for hepatitis B. Liver Int. 2011; 31(8):1179-90. DOI: 10.1111/j.1478-3231.2011.02559.x. View

Nanwa N, Kwong J, Feld J, Wu C, Sander B . The mean attributable health care costs associated with hepatitis B virus in Ontario, Canada: A matched cohort study. Can Liver J. 2022; 5(3):339-361. PMC: 9473555. DOI: 10.3138/canlivj-2021-0029. View

Woo G, Tomlinson G, Yim C, Lilly L, Therapondos G, Wong D . Health state utilities and quality of life in patients with hepatitis B. Can J Gastroenterol. 2012; 26(7):445-51. PMC: 3395446. DOI: 10.1155/2012/736452. View

Blachier M, Leleu H, Peck-Radosavljevic M, Valla D, Roudot-Thoraval F . The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013; 58(3):593-608. DOI: 10.1016/j.jhep.2012.12.005. View

10.

Potosek J, Curry M, Buss M, Chittenden E . Integration of palliative care in end-stage liver disease and liver transplantation. J Palliat Med. 2014; 17(11):1271-7. PMC: 4229716. DOI: 10.1089/jpm.2013.0167. View

11.

Chu C, Liaw Y . Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepat. 2007; 14(3):147-52. DOI: 10.1111/j.1365-2893.2006.00810.x. View

12.

Veenstra D, Sullivan S, Clarke L, Iloeje U, Tafesse E, Di Bisceglie A . Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics. 2007; 25(11):963-77. DOI: 10.2165/00019053-200725110-00006. View

13.

Liaw Y, Tai D, Chu C, Chen T . The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology. 1988; 8(3):493-6. DOI: 10.1002/hep.1840080310. View

14.

Lin S, Sheen I, Chien R, Chu C, Liaw Y . Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999; 29(3):971-5. DOI: 10.1002/hep.510290312. View

15.

Chan H, Fung S, Seto W, Chuang W, Chen C, Kim H . Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2017; 1(3):185-195. DOI: 10.1016/S2468-1253(16)30024-3. View

16.

Wong W, Pechivanoglou P, Wong J, Bielecki J, Haines A, Erman A . Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials. Syst Rev. 2019; 8(1):207. PMC: 6699129. DOI: 10.1186/s13643-019-1126-1. View

17.

Chien R, Yeh C, Sheen I, Chiou H, Chu C, Liaw Y . Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002; 35(6):1522-7. DOI: 10.1053/jhep.2002.33638. View

18.

Gigi E, Lalla T, Orphanou E, Sinakos E, Vrettou E, Raptopoulou-Gigi M . Long term follow-up of a large cohort of inactive HBsAg (+)/ HBeAg (-)/ anti-HBe (+) carriers in Greece. J Gastrointestin Liver Dis. 2007; 16(1):19-22. View

19.

McMahon B, Holck P, Bulkow L, Snowball M . Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med. 2001; 135(9):759-68. DOI: 10.7326/0003-4819-135-9-200111060-00006. View

20.

Iloeje U, Yang H, Su J, Jen C, You S, Chen C . Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006; 130(3):678-86. DOI: 10.1053/j.gastro.2005.11.016. View